Illustration: Gabriella Turrisi/Axios
Pharma giant Roche (Swiss: ROG) is considering divesting Flatiron, the cancer data startup it acquired for $2.1 billion in 2018, the Financial Times reports.
Why it matters: Flatiron was heralded as an example of the promise of Big Pharma harnessing data, but the business has struggled to make money.
